25.03
0.34 (1.38%)
| Previous Close | 24.69 |
| Open | 24.97 |
| Volume | 1,344,660 |
| Avg. Volume (3M) | 2,628,553 |
| Market Cap | 2,539,917,824 |
| Price / Sales | 42.69 |
| Price / Book | 2.66 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Operating Margin (TTM) | -1,596.87% |
| Diluted EPS (TTM) | -4.61 |
| Quarterly Revenue Growth (YOY) | 0.80% |
| Total Debt/Equity (MRQ) | 14.08% |
| Current Ratio (MRQ) | 8.81 |
| Operating Cash Flow (TTM) | -351.38 M |
| Levered Free Cash Flow (TTM) | -185.90 M |
| Return on Assets (TTM) | -19.05% |
| Return on Equity (TTM) | -38.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Beam Therapeutics Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.22% |
| % Held by Institutions | 98.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mwg Management Ltd. | 30 Sep 2025 | 2,266,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 219.62%) | Buy |
| Median | 46.00 (83.78%) | |
| Low | 35.00 (Evercore ISI Group, 39.83%) | Buy |
| Average | 53.67 (114.42%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 25.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 24 Nov 2025 | 35.00 (39.83%) | Buy | 23.62 |
| HC Wainwright & Co. | 10 Oct 2025 | 80.00 (219.62%) | Buy | 26.32 |
| 15 Sep 2025 | 80.00 (219.62%) | Buy | 21.28 | |
| JP Morgan | 09 Oct 2025 | 46.00 (83.78%) | Buy | 27.87 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2025 | Announcement | Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference |
| 04 Nov 2025 | Announcement | Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates |
| 03 Nov 2025 | Announcement | Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |